ARHGAP29 Activators
ARHGAP29 activators are diverse compounds that indirectly promote the functional activity of ARHGAP29 by modulating various cellular signaling pathways and cytoskeletal dynamics. For instance, Phorbol 12-myristate 13-acetate (PMA) as a protein kinase C (PKC) activator, could lead to increased RhoA turnover, thereby enhancing ARHGAP29's GTPase-activating role towards RhoA. Similarly, Forskolin's activation of adenylyl cyclase raises cAMP levels, which in turn activates protein kinase A (PKA). PKA then influences the actin cytoskeleton and cellular adhesion dynamics, indirectly augmenting ARHGAP29's regulatory function in these processes. Y-27632, a ROCK inhibitor, and NSC 23766, which disrupts Rac1-GEF interaction, both contribute to a reduced counteractive tension on the cytoskeleton or less active Rac1, respectively, which might indirectly enhance ARHGAP29's GAP activity. Additionally, compounds like ML141, LY294002, and PD 98059, which inhibit Cdc42, PI3K, and MEK respectively, may foster a cellular environment that indirectly supports ARHGAP29's role in actin cytoskeletal reorganization by dampening alternative Rho GTPase signaling pathways.
Furthermore, the actin cytoskeleton's architecture is influenced by compounds such as Blebbistatin and CK-636, which inhibit myosin II ATPase and the Arp2/3 complex, respectively, reducing contractility and actin polymerization. This could lead to an enhanced need for ARHGAP29's activity in maintaining cytoskeletal integrity. Jasplakinolide, by stabilizing actin filaments, might also necessitate increased ARHGAP29-mediated RhoA inactivation to balance the cytoskeletal dynamics. Inhibitors like SB 203580, which targets p38 MAPK, could shift cellular responses to favor ARHGAP29's role in stress fiber formation and actin remodeling. Collectively, these ARHGAP29 activators function through intricate cellular mechanisms that converge on the regulation of the actin cytoskeleton, indirectly necessitating or enhancing the activity of ARHGAP29 without affecting its expression levels or requiring direct activation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA functions as a diacylglycerol analog, activating protein kinase C (PKC). PKC activation can lead to the phosphorylation of downstream effectors that regulate the GTPase activity of Rho family proteins. ARHGAP29 is a GTPase activating protein for RhoA, thus PMA may enhance ARHGAP29's activity by increasing RhoA turnover. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylyl cyclase, increasing cAMP levels, which in turn activates PKA. PKA phosphorylation can influence the actin cytoskeleton and cellular adhesion dynamics. Since ARHGAP29 regulates cytoskeletal remodeling, Forskolin's effect on PKA may indirectly enhance ARHGAP29's activity in cytoskeletal regulation. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a ROCK inhibitor that inhibits the downstream Rho-associated kinase. Inhibition of ROCK leads to a decrease in tension within the actin cytoskeleton. ARHGAP29, being a Rho GTPase activating protein, would be indirectly enhanced due to the reduced counteractive tension from ROCK, promoting actin remodeling. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $151.00 $609.00 | 75 | |
NSC 23766 inhibits the interaction between Rac1 and its Guanine nucleotide exchange factors (GEFs), leading to decreased active Rac1. ARHGAP29 has GAP activity towards RhoA, and with Rac1 being less active, ARHGAP29's role in actin cytoskeleton dynamics would be indirectly enhanced by shifting the balance towards RhoA inactivation. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $137.00 $512.00 | 7 | |
ML141 is a potent and selective inhibitor of Cdc42 GTPase. By inhibiting active Cdc42, the cellular dynamics favor activities driven by RhoA. Since ARHGAP29 is a GAP for RhoA, inhibiting Cdc42 would indirectly enhance ARHGAP29's functional activity related to actin cytoskeletal reorganization. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that blocks the PI3K/Akt pathway, leading to alterations in the actin cytoskeleton. As ARHGAP29 plays a role in actin cytoskeletal dynamics, the inhibition of PI3K could create a cellular context where ARHGAP29's GAP activity towards RhoA is enhanced as part of compensatory cytoskeletal rearrangements. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a specific inhibitor of MEK, which blocks the activation of the MAPK/ERK pathway. Inhibition of ERK activity can lead to changes in cytoskeletal organization. Since ARHGAP29 is involved in the regulation of the actin cytoskeleton, its activity may be indirectly enhanced by the reduction in competitive MAPK/ERK signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a specific inhibitor of p38 MAPK. The inhibition of p38 MAPK can influence actin dynamics and cellular stress responses. ARHGAP29, as a regulator of the actin cytoskeleton through its GAP activity, may have enhanced function when stress-related p38 MAPK signaling is diminished. | ||||||
(±)-Blebbistatin | 674289-55-5 | sc-203532B sc-203532 sc-203532A sc-203532C sc-203532D | 5 mg 10 mg 25 mg 50 mg 100 mg | $183.00 $313.00 $464.00 $942.00 $1723.00 | 7 | |
Blebbistatin is an inhibitor of myosin II ATPase activity. By inhibiting myosin II, it reduces cellular contractility, affecting actin cytoskeleton architecture. ARHGAP29, which modulates the actin cytoskeleton, could have an enhanced regulatory role when myosin II-driven tension is reduced. | ||||||
Jasplakinolide | 102396-24-7 | sc-202191 sc-202191A | 50 µg 100 µg | $184.00 $305.00 | 59 | |
Jasplakinolide stabilizes actin filaments and can lead to increased actin polymerization. This stabilization could enhance ARHGAP29 activity by increasing the requirement for its GAP activity toward RhoA to regulate the enhanced cytoskeletal tension. | ||||||